[Effect of indomethacin on natural killer(NK) cell and T lymphocyte subsets from patients with hepatocellular carcinoma].
Twenty-one patients with advanced hepatocellular carcinoma were randomly divided into two groups. They were orally given tegafur 200 mg three times a day with(Group I, n = 11) or without(Group II, n = 10) indomethacin 25 mg three times a day for 7 days. Before and after the therapies the NK cell and T-lymphocyte subset activity in peripheral blood were measured. The results showed that NK cell activity in Group I was significantly higher than that in Group II(P < 0.01) and that before the treatment as well(P < 0.05). T-lymphocyte subsets had no significant difference between the two groups and before or after the therapy. It is suggested that the indomethacin might improve the NK activity of the patients with advanced hepatocellular carcinoma.
Yuan
W J
WJ
Department of Internal Medicine, Xiangya Hospital, Hunan Medical University, Changsha 410008.
Chen
F Y
FY
Zhang
G Y
GY
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D005641:Tegafur / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D007213:Indomethacin